Genfit: bright red after the announcements

(Boursier.com) — In last position on the SRD, Genfit stumbles by 6% to 3.06 euros after its annual point. As indicated in previous communications, Genfit expects to receive milestone payments in 2024 totaling approximately €89 million (including the €13.3 million milestone payment already received in February 2024), subject to the approval and marketing of elafibranor in the PBC

Oddo BHF talks about a publication that aims to be reassuring. The broker does not note any clinical discrepancy. The PDUFA date of June is key to the group’s stock market performance this year. The analyst still thinks that the risk reward is attractive given the company’s current valuation, which leads him to maintain his ‘outperform’ recommendation. Kepler Cheuvreux remains ‘buy’ with a target reduced from 9.3 to 8.2 euros.